Janux Therapeutics Inc (JANX) - Total Assets
Based on the latest financial reports, Janux Therapeutics Inc (JANX) holds total assets worth $1.02 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See JANX total equity for net asset value and shareholders' equity analysis.
Janux Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Janux Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Janux Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Janux Therapeutics Inc's total assets of $1.02 Billion consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.6% |
| Accounts Receivable | $5.38 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Janux Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Janux Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Janux Therapeutics Inc's current assets represent 97.4% of total assets in 2024, an increase from 96.9% in 2019.
- Cash Position: Cash and equivalents constituted 40.6% of total assets in 2024, down from 96.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Janux Therapeutics Inc Competitors by Total Assets
Key competitors of Janux Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Janux Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 35.86 | 38.80 | 5.05 |
| Quick Ratio | 35.86 | 38.80 | 5.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $970.25 Million | $649.15 Million | $12.88 Million |
Janux Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Janux Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.74 |
| Asset Growth Rate (YoY) | 179.0% |
| Total Assets | $1.06 Billion |
| Market Capitalization | $790.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Janux Therapeutics Inc's assets below their book value (0.74x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Janux Therapeutics Inc's assets grew by 179.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Janux Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Janux Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.06 Billion | +179.05% |
| 2023-12-31 | $380.41 Million | +4.50% |
| 2022-12-31 | $364.01 Million | -4.16% |
| 2021-12-31 | $379.82 Million | +2242.13% |
| 2020-12-31 | $16.22 Million | +2288.37% |
| 2019-12-31 | $679.00K | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment o… Read more